Who owns Milestone Pharmaceuticals Inc?
- Ticker: MIST
- CUSIP Number: 59935v107
Tip: Access positions for across all investors
Analyze quarterly positions in Milestone Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv
Download as Excel
Top investors of Milestone Pharmaceuticals stock
Who bought or sold Milestone Pharmaceuticals Inc this quarter?
| Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
|---|---|---|---|---|---|
| BlackRock | 5.0M | $8.9M | 79% | Mar 2024 |
|
| Millennium Management | 2.9M | $5.1M | 65% | Mar 2024 |
|
| Alta Fundamental Advisers | 2.4M | $4.2M | 102% | Mar 2024 |
|
| Lion Point Capital | 2.3M | $4.1M | 39% | Mar 2024 |
|
| Citadel Advisors | 2.3M | $4.1M | 852% | Mar 2024 |
|
| OrbiMed Advisors | 2.0M | $3.6M | 100% | Mar 2024 |
|
| Nantahala Capital Management | 1.8M | $3.1M | 100% | Mar 2024 |
|
| Goldman Sachs Group | 1.4M | $2.4M | 0% | Mar 2024 |
|
| Bleichroeder | 1.3M | $2.2M | 0% | Dec 2023 |
|
| Altium Capital Management | 1.2M | $2.2M | 100% | Mar 2024 |
|
| Morgan Stanley | 820k | $1.5M | 17% | Mar 2024 |
|
| Velan Capital Investment Management | 650k | $1.2M | 100% | Mar 2024 |
|
| BML Capital Management | 606k | $1.1M | 37% | Mar 2024 |
|
| Monashee Investment Management | 500k | $895k | 100% | Mar 2024 |
|
| Ikarian Capital | 466k | $834k | 1% | Mar 2024 |
|
| Boxer Capital | 309k | $553k | 0% | Mar 2024 |
|
| Bank Of Montreal | 273k | $787k | 100% | Mar 2024 |
|
| ADAR1 Capital Management | 203k | $362k | 100% | Mar 2024 |
|
| Ancora Advisors | 60k | $107k | 20% | Mar 2024 |
|
| Envestnet Asset Management | 52k | $93k | 173% | Mar 2024 |
|
| Dimensional Fund Advisors | 40k | $71k | -46% | Mar 2024 |
|
| Boothbay Fund Management | 31k | $55k | 12% | Mar 2024 |
|
| Northern Trust | 28k | $51k | 100% | Mar 2024 |
|
| Clear Creek Financial Management | 25k | $45k | -21% | Mar 2024 |
|
| Pvg Asset Management | 19k | $32k | 25% | Dec 2023 |
|
| Virtu Financial | 19k | $31k | 100% | Dec 2023 |
|
| Geode Capital Management | 18k | $32k | 0% | Mar 2024 |
|
| Bnp Paribas Arbitrage, Snc | 17k | $30k | 177% | Mar 2024 |
|
| Beta Wealth | 14k | $24k | 0% | Dec 2023 |
|
| XTX Topco | 13k | $24k | 100% | Mar 2024 |
|
| Creative Planning | 13k | $23k | 0% | Mar 2024 |
|
| Federation des caisses Desjardins du Quebec | 11k | $19k | 100% | Mar 2024 |
|
| Valeo Financial Advisors | 10k | $17k | 0% | Mar 2024 |
|
| Advisor Group Holdings | 6.0k | $11k | -57% | Mar 2024 |
|
| National Bank Of Canada /fi/ | 3.9k | $6.8k | 0% | Dec 2023 |
|
| UBS Group | 2.6k | $4.7k | 100% | Mar 2024 |
|
| Simplex Trading | 478.00 | $0 | -56% | Mar 2024 |
|
| ICA Group Wealth Management | 200.00 | $358.000000 | 0% | Mar 2024 |
|
| Qube Research & Technologies | 194.00 | $347.007800 | 0% | Mar 2024 |
|
| Barclays | 100.00 | $0 | -100% | Mar 2024 |
|
| Oliver Lagore Vanvalin Investment Group | 100.00 | $179.000000 | 0% | Mar 2024 |
|
Who sold out of Milestone Pharmaceuticals?
| Fund or Company Name | Date Sold | Shares Held | Valued At |
|---|---|---|---|
| VR Adviser | Dec 2023 | 925k | $1.5M |
| Jpmorgan Chase & Co | Dec 2023 | 11k | $18k |